Nicotinamide mononucleotide adenylyltransferase2 overexpression enhances colorectal cancer cell-kill by Tiazofurin

Cancer Gene Therapy

Volumn 20, Issue 7, 2013, Pages 403-412

  Kusumanchi, P ^a,b   Zhang, Y ^b   Jani, M B ^a   Jayaram, N H ^b   Khan, R A ^a,b   Tang, Y ^b   Antony, A C ^a,b   Jayaram, H N ^a,b  

^a RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Folate receptors; IMP dehydrogenase inhibitor; Nanoparticles; Silencing human nicotinamide 5' mononucleotide adenylyltransferase; Targeted therapy; Tiazofurin

Indexed keywords

FOLIC ACID; NANOPARTICLE; NICOTINAMIDE MONONUCLEOTIDE ADENYLYLTRANSFERASE2; NUCLEOTIDYLTRANSFERASE; TIAZOFURIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER GENE THERAPY; CELL KILLING; CELL STRAIN CACO 2; CELL STRAIN HT29; COLORECTAL CANCER; CYTOTOXICITY; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL SURVIVAL; COLORECTAL NEOPLASMS; DRUG CARRIERS; DRUG RESISTANCE, NEOPLASM; FLUORESCEINS; FOLIC ACID TRANSPORTERS; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; GUANOSINE TRIPHOSPHATE; HUMANS; IMP DEHYDROGENASE; ISOENZYMES; NANOPARTICLES; NICOTINAMIDE-NUCLEOTIDE ADENYLYLTRANSFERASE; PROTEIN TRANSPORT; RIBAVIRIN; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84880918449     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2013.33     Document Type: Article

References (45)

1. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T et al. Multicenter International Study of Oxaliplatin/5-Fluorouracil/ Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. N Engl J Med 2004; 350: 2343-2351.
2. Wu C, Goldberg RM. Colorectal cancer in 2012: revisiting landmark trials and identifying new therapies. Nat Rev Clin Oncol 2013; 10: 71-72.
3. de Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 2012; 13: 1255-1233.
4. Arkenau HT, Arnold D, Cassidy J, Diaz-Rubio E, Douillard JY, Hochster H et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol 2008; 26: 5910-5917.
5. Emanuelli M, Carnevali F, Saccucci F, Pierella F, Amici A, Raffaelli N et al. Molecular cloning, chromosomal localization, tissue mRNA levels, bacterial expression, and enzymatic properties of human NMN adenylyltransferase. J Biol Chem 2001; 276: 406-412. (Pubitemid 32050333)
6. Schweiger M, Hennig K, Lerner F, Niere M, Hirsch-Kauffmann M, Specht T et al. Characterization of recombinant human nicotinamide mononucleotide adenylyltransferase (NMNAT), a nuclear enzyme essential for NAD synthesis. FEBS Lett 2001; 492: 95-100. (Pubitemid 32206727)
7. Raffaelli N, Sorci L, Amici A, Emanuelli M, Mazzola F, Magni G. Identification of a novel human nicotinamide mononucleotide adenylyltransferase. Biochem Biophys Res Commun 2002; 297: 835-840. (Pubitemid 35230325)
8. Zhang X, Kurnasov OV, Karthikeyan S, Grishin NV, Osterman AL, Zhang H. Structural characterization of a human cytosolic NMN/NaMN adenylyltransferase and implication in human NAD biosynthesis. J Biol Chem 2003; 278: 13503-13511. (Pubitemid 36800125)
9. Yalowitz JA, Xiao S, Biju MP, Antony AC, Cummings OW, Deeg MA et al. Characterization of human brain nicotinamide 50-mononucleotide adenylyltransferase-2 and expression in human pancreas. Biochem J 2004; 377: 317-326. (Pubitemid 38142187)
10. Berger F, Lau C, Dahlmann M, Ziegler M. Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms. J Biol Chem 2005; 280: 36334-36341. (Pubitemid 41633907)
11. Cooney DA, Jayaram HN, Gebeyehu G, Betts CR, Kelley JA, Marquez VE et al. The conversion of 2-D-ribofuranosylthiazole-4-carboxamide to an analog of NAD with potent IMP dehydrogenase-inhibitory properties. Biochem Pharmacol 1982; 31: 2133-2136.
12. Jayaram HN, Smith AL, Glazer RI, Johns DG, Cooney DA. Studies on the mechanism of action of 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193)-II. Relationship between dose level and biochemical effects in P388 leukemia in vivo. Biochem Pharmacol 1982; 31: 3839-3845. (Pubitemid 13218458)
13. Jayaram HN. Biochemical mechanisms of resistance to tiazofurin. Adv Enzyme Regul 1985; 24: 67-89.
14. Jayaram HN, Zhen W, Gharehbaghi K. Biochemical consequences of resistance to tiazofurin in human myelogenous leukemic K562 cells. Cancer Res 1993; 53: 2344-2348. (Pubitemid 23156823)
15. Tricot GJ, Jayaram HN, Lapis E, Natsumeda Y, Nichols CR, Kneebone P et al. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'- phosphate dehydrogenase activity. Cancer Res 1989; 49: 3696-3701. (Pubitemid 19178199)
16. Wright DG, Boosalis MS, Waraska K, Oshry LJ, Weintraub LR, Vosburgh E. Tiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis. Anticancer Res 1996; 16: 3349-3351.
17. Grifantini M, Tiazofurine ICN. Pharmaceuticals. Curr Opin Investig Drugs 2000; 1: 257-262.
18. Maroun JA, Eisenhauer E, Cripps C, Maksymiuk A. Phase II study of tiazofurin in colorectal cancer: A National Cancer Institute of Canada study. Cancer Treat Rep 1987; 71: 1297-1298.
19. Jayaram HN, Lapis E, Tricot G, Kneebone P, Paulik E, Zhen W et al. Clinical pharmaco kinetic study of tiazofurin administered as a 1-hour infusion. Int J Cancer 1992; 51: 182-188.
20. Zhen W, Jayaram HN, Weber G. Antitumor activity of tiazofurin in human colon carcinoma HT-29. Cancer Invest 1992; 10: 505-511.
21. Lapis KY, Bocsi J, Tovari J, Bartha I, Timar J, Raso E. Antiinvasive effects of Tiazofurin on liver-metastatic human colon carcinoma xenografts. Anticancer Res 1996; 16: 3323-3331. (Pubitemid 27085077)
22. Ahluwalia GS, Jayaram HN, Plowman JP, Cooney DA, Johns DG. Studies on the mechanism of action of 2-D-ribofuranosylthiazole-4-carboxamide-V. Factors governing the response of murine tumors to tiazofurin. Biochem Pharmacol 1984; 33: 1195-1203.
23. Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta 1995; 1233: 134-144.
24. Zhang Y, Guo L, Roeske RW, Antony AC, Jayaram HN. Pteroyl-g- glutamatecysteine synthesis and its application in folate receptor-mediated cancer cell targeting using folate-tethered liposomes. Anal Biochem 2004; 332: 168-177. (Pubitemid 39099484)
25. Xiang G, Wu J, Lu Y, Liu Z, Lee RJ. Synthesis and evaluation of novel ligand for folate mediated targeting liposomes. Int J Pharm 2008; 356: 29-36.
26. Suzuki R, Takizawa T, Kuwata Y, Mutoh M, Ishiguro N, Utoguchi N et al. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposomes. Int J Pharm 2008; 346: 143-150. (Pubitemid 350101994)
27. Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 2008; 108: 619-626.
28. Shia J, Klimstra DS, Nitzkorski JR, Low PS, Gonen M, Landmann R et al. Immuno histochemical expression of folate receptor alpha in colorectal carcinoma: patterns and biological significance. Hum Pathol 2008; 39: 498-505. (Pubitemid 351375020)
29. D'Angelica M, Ammori J, Gonen M, Klimstra DS, Low PS, Murphy L et al. Folate receptor-a expression in resectable hepatic colorectal cancer metastases: patterns and significance. Modern Pathol 2011; 24: 1221-1228.
30. Xiao S, Tang YS, Khan RA, Zhang Y, Kusumanchi P, Stabler SP et al. Influence of physiologic folate deficiency on human papillomavirus type 16 (HPV16)- harboring human keratinocytes in vitro and in vivo. J Biol Chem 2012; 287: 12559-12577.
31. Antony A, Tang YS, Khan RA, Biju MP, Xiao X, Li QJ et al. Translational upregulation of folate receptors is mediated by homocysteine via RNA-heterogeneous nuclear ribonucleoprotein E1 interactions. J Clin Invest 2004; 113: 285-301. (Pubitemid 38544213)
32. Egan RW. Hydrophile-lipophile balance and critical micelle concentration as key factors influencing surfactant disruption of mitochondrial membranes. J Biol Chem 1976; 251: 4442-4447.
33. Gharehbaghi K, Sreenath A, Hao Z, Paull KD, Szekers T, Cooney DA et al. Comparison of biochemical parameters of benzamide riboside, a new inhibitor of IMP dehydrogenase, with tiazofurin and selenazofurin. Biochem Pharmacol 1994; 48: 1413-1419. (Pubitemid 24318146)
34. Nagai M, Natsumeda Y, Weber G. Proliferation-linked regulation of type II IMP dehydrogenase gene in human normal lymphocytes and HL-60 leukemic cells. Cancer Res 1992; 52: 258-261.
35. Franchetti P, Cappellacci L, Pasqualini M, Petrelli R, Jayaprakasan V, Jayaram HN et al. Synthesis, conformational analysis, and biological activity of new analogues of thiazole-4-carboxamide adenine dinucleotide (TAD) as IMP dehydrogenase inhibitors. Bioorg Med Chem 2005; 13: 2045-2053. (Pubitemid 40261126)
36. Ahluwalia GS, Cooney DA, Marquez VE, Jayaram HN, Johns DG. Studies on the mechanism of action of tiazofurin (2-beta-D-ribofuranosylthiazole-4- carboxamide). VI. Biochemical and pharmacological studies on the degradation of thiazole-4- carboxamide adenine dinucleotide (TAD). Biochem Pharmacol 1986; 35: 3783-3790. (Pubitemid 17180428)
37. Pillwein K, Schuchter K, Ressmann G, Gharehbaghi K, Knoflach A, Cermak B et al. Cytotoxicity, differentiating activity and metabolism of tiazofurin in human neuroblastoma cells. Int J Cancer 1993; 55: 92-95. (Pubitemid 23261712)
38. Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001; 19: 424-436. (Pubitemid 32525189)
39. Low PS, Antony AC. Folate receptor-targeted drugs for cancer and inflammatory diseases. Adv Drug Deliv Rev 2004; 56: 1055-1058. (Pubitemid 38496506)
40. Anderson RM, Bitterman KJ, Wood JG, Medvedik O, Cohen H, Lin SS et al. Manipulation of a nuclear NAD+ salvage pathway delays aging without altering steady-state NAD+ levels. Biol Chem 2002; 277: 18881-18890. (Pubitemid 34952448)
41. Guo X, Eans TRJ, Sumanth S, Armesilla AL, Darling JL, Schatzlein A et al. In vitro evaluation of cancer-specific NF-kB-CEA enhancer-promoter system for 5-fluorouracil prodrug gene therapy in colon cancer cells. Br J Cancer 2007; 97: 745-754. (Pubitemid 47396284)
42. Wang Y, Canine BF, Hatefi A. HSV-TK/GCV cancer suicide gene therapy by a designed recombinant multifunctional vector. Nanomedicine 2011; 7: 193-200.
43. Zhang J, Wei F, Wang H, Li H, Qiu W, Ren P et al. A novel oncolytic adenovirus expressing Escherichia coli cytosine deaminase exhibits potent antitumor effect on human solid tumors. Cancer Biother Radiopharm 2010; 25: 487-495.
44. Sun XL, Jayaram HN, Gharehbaghi K, Li QJ, Xiao X, Antony AC. Modulation of the cytotoxicity of 30-azido-30-deoxythymidine and methotrexate after transduction of folate receptor cDNA into human cervical carcinoma: Identification of a correlation between folate receptor expression and thymidine kinase activity. Cancer Res 1999; 59: 940-946. (Pubitemid 29086752)
45. Sega EL, Low PS. Tumor detection using folate receptor-targeted imaging agents. Cancer Metastasis Re 2008; 27: 655-664.